Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
复制标题
DOI：
10.1161/01.cir.95.5.1126
复制
发表时间：
1997-03-04
期刊：
影响因子：
37.8
通讯作者：
Taylor, RR
中科院分区：
文献类型：
--
作者：
ODriscoll, G;Green, D;Taylor, RR
背景降胆固醇治疗可以改善动脉粥样硬化患者的心血管发病率和死亡率。尽管其机制尚不清楚，但这些益处先于脉管系统的宏观变化。新出现的内皮功能改善的证据需要证实；特别是，目前尚不清楚在开始治疗后，这种改善能多早被发现。方法与结果：本研究采用随机、双盲、安慰剂对照交叉研究，通过应力测量容积图评估辛伐他汀（每天20 mg，持续4周）对内皮依赖性和内皮非依赖性血管舒张的影响，以及对血清总胆固醇（6.0 ~ 10.0 mmol/L）中度升高受试者前臂血管中一氧化氮合成抑制剂n-g -单甲基-L-精氨酸（L- nmma）的反应。开放治疗3个多月后重复研究。当结果以输注组相对于未输注组的血流变化百分比表示时，辛伐他汀治疗4周后，血管扩张剂对乙酰胆碱的反应显著增加(P
Background Cholesterol-lowering therapy can improve cardiovascular morbidity and mortality in patients with atherosclerosis. Although the mechanisms responsible are unclear, these benefits precede macroscopic changes in the vasculature. Emerging evidence that improvement in endothelial function may occur requires substantiation; in particular, it is unclear how early any such improvement would be detectable after initiation of therapy.Methods and Results This randomized, double-blind, placebo-controlled crossover study evaluated the effect of simvastatin (20 mg daily for 4 weeks) on endothelium-dependent and endothelium-independent vasodilation and on the response to the inhibitor of nitric oxide synthesis, N-G-monomethyl-L-arginine (L-NMMA), in the forearm vasculature of subjects with moderate elevation of total serum cholesterol (6.0 to 10.0 mmol/L) by use of strain-gauge plethysmography. Studies were repeated after 3 more months of open therapy. When the results are expressed as percentage changes in flow in the infused arm relative to the noninfused arm, the vasodilator response to acetylcholine was significantly increased after 4 weeks of treatment with simvastatin (P